kp-001
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 15, 2023 (NCT06227832)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285005 | Phase 3 | Feb 26, 2026 | Kaken Pharmaceutical Co.,Ltd. |
| NCT06821698 | Phase 1 | Feb 10, 2025 | Kaken Pharmaceutical Co.,Ltd. |
| NCT06619054 | Phase 1 | Oct 24, 2024 | Kaken Pharmaceutical Co.,Ltd. |
| NCT06649942 | Phase 1 | Oct 1, 2024 | Kaken Pharmaceutical Co.,Ltd., Parexel |
| NCT06227832 | Phase 1 | Dec 15, 2023 | Kaken Pharmaceutical Co.,Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kaken Pharmaceutical Co.,Ltd. | For profit | 5 | 5 | 2 | 2023 |
| Parexel | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1